130 related articles for article (PubMed ID: 27230087)
1. Preliminary report on a cost-utility analysis of revascularization by percutaneous coronary intervention for ischemic heart disease.
Takura T; Tachibana K; Isshiki T; Sumitsuji S; Kuroda T; Mizote I; Ide S; Nanto S
Cardiovasc Interv Ther; 2017 Apr; 32(2):127-136. PubMed ID: 27230087
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.
Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW;
Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
[TBL] [Abstract][Full Text] [Related]
4. Economic Evaluation of Complete Revascularization for Patients with Multivessel Disease Undergoing Primary Percutaneous Coronary Intervention.
Barton GR; Irvine L; Flather M; McCann GP; Curzen N; Gershlick AH;
Value Health; 2017 Jun; 20(6):745-751. PubMed ID: 28577691
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve.
Fearon WF; Shilane D; Pijls NH; Boothroyd DB; Tonino PA; Barbato E; Jüni P; De Bruyne B; Hlatky MA;
Circulation; 2013 Sep; 128(12):1335-40. PubMed ID: 23946263
[TBL] [Abstract][Full Text] [Related]
6. Coronary bypass surgery versus percutaneous coronary intervention: cost-effectiveness in Iran: a study in patients with multivessel coronary artery disease.
Javanbakht M; Bakhsh RY; Mashayekhi A; Ghaderi H; Sadeghi M
Int J Technol Assess Health Care; 2014 Oct; 30(4):366-73. PubMed ID: 25401422
[TBL] [Abstract][Full Text] [Related]
7. Sustained 3-Year Benefits in Quality of Life After Percutaneous Coronary Interventions in the Elderly: A Prospective Cohort Study.
Yan BP; Chan LLY; Lee VWY; Yu CM; Wong MCS; Sanderson J; Reid CM
Value Health; 2018 Apr; 21(4):423-431. PubMed ID: 29680099
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical outcomes, health-related quality of life, and costs in different treatment modalities of stable coronary artery disease.
Stenvall H; Tierala I; Räsänen P; Laine M; Sintonen H; Roine RP
Eur Heart J Qual Care Clin Outcomes; 2017 Jan; 3(1):74-82. PubMed ID: 28927186
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Cardiac Telerehabilitation With Relapse Prevention for the Treatment of Patients With Coronary Artery Disease in the Netherlands.
Brouwers RWM; van der Poort EKJ; Kemps HMC; van den Akker-van Marle ME; Kraal JJ
JAMA Netw Open; 2021 Dec; 4(12):e2136652. PubMed ID: 34854907
[TBL] [Abstract][Full Text] [Related]
10. Improving the quality of percutaneous revascularisation in patients with multivessel disease in Australia: cost-effectiveness, public health implications, and budget impact of FFR-guided PCI.
Siebert U; Arvandi M; Gothe RM; Bornschein B; Eccleston D; Walters DL; Rankin J; De Bruyne B; Fearon WF; Pijls NH; Harper R
Heart Lung Circ; 2014 Jun; 23(6):527-33. PubMed ID: 24560401
[TBL] [Abstract][Full Text] [Related]
11. [Evaluation of utility index of quality of life (QOL) in prostate cancer patients: comparison of QOL utility index EuroQol-5D (EQ-5D) and visual analogue scale (VAS) with health-related QOL questionnaires SF-36 and EPIC].
Akakura K; Matsuzaki K; Kobayashi T; Kitoh H; Mizoguchi K; Tomikawa G; Takura T; Kawabuchi K
Nihon Hinyokika Gakkai Zasshi; 2011 Jan; 102(1):9-13. PubMed ID: 21520631
[TBL] [Abstract][Full Text] [Related]
12. Kidney Function Does Not Modify the Favorable Quality of Life Changes Associated With Revascularization for Coronary Artery Disease: Cohort Study.
James MT; Wilton SB; Clement FM; Ghali WA; Knudtson ML; Tan Z; Tonelli M; Hemmelgarn BR; Norris CM;
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27436303
[TBL] [Abstract][Full Text] [Related]
13. Social and Economic Costs and Health-Related Quality of Life in Patients With Acute Coronary Syndrome.
Sheikhgholami S; Ebadifardazar F; Rezapoor A; Tajdini M; Salarifar M
Value Health Reg Issues; 2021 May; 24():123-129. PubMed ID: 33571726
[TBL] [Abstract][Full Text] [Related]
14. Establishing the cost-effectiveness of percutaneous coronary intervention for chronic total occlusion in stable angina: a decision-analytic model.
Gada H; Whitlow PL; Marwick TH
Heart; 2012 Dec; 98(24):1790-7. PubMed ID: 23038791
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial.
McCreanor V; Nowbar A; Rajkumar C; Barnett AG; Francis D; Graves N; Boden WE; Weintraub WS; Al-Lamee R; Parsonage WA
BMJ Open; 2021 Feb; 11(2):e044054. PubMed ID: 33563623
[TBL] [Abstract][Full Text] [Related]
16. Quality of life in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention--radial versus femoral access (from the OCEAN RACE Trial).
Koltowski L; Koltowska-Haggstrom M; Filipiak KJ; Kochman J; Golicki D; Pietrasik A; Huczek Z; Balsam P; Scibisz A; Opolski G
Am J Cardiol; 2014 Aug; 114(4):516-21. PubMed ID: 25015695
[TBL] [Abstract][Full Text] [Related]
17. Treatment, outcomes, costs, and quality of life of women and men with acute coronary syndromes who have undergone percutaneous coronary intervention: results from the antiplatelet therapy observational registry.
Bakhai A; Ferrières J; James S; Iñiguez A; Mohácsi A; Pavlides G; Belger M; Norrbacka K; Sartral M
Postgrad Med; 2013 Mar; 125(2):100-7. PubMed ID: 23816776
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations.
Ono Y; Osuga K; Takura T; Nakamura M; Shibamoto K; Yamamoto A; Fujiwara H; Mimura H; Tomiyama N
J Vasc Interv Radiol; 2016 Jun; 27(6):831-7. PubMed ID: 26972615
[TBL] [Abstract][Full Text] [Related]
19. Use of the U.S. and U.K. scoring algorithm for the EuroQol-5D in an economic evaluation of cardiac care.
Shrive FM; Ghali WA; Johnson JA; Donaldson C; Manns BJ
Med Care; 2007 Mar; 45(3):269-73. PubMed ID: 17304086
[TBL] [Abstract][Full Text] [Related]
20. Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial).
Bradley SM; Chan PS; Hartigan PM; Nallamothu BK; Weintraub WS; Sedlis SP; Dada M; Maron DJ; Kostuk WJ; Berman DS; Teo KK; Mancini GB; Boden WE; Spertus JA
Am J Cardiol; 2015 Jul; 116(2):167-73. PubMed ID: 25960375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
